Lifirafenib

SCHEMBL29750807

O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O.O=C1CCc2c(Oc3ccc4c(c3)[C@@H]3[C@H](O4)[C@H]3c3nc4ccc(C(F)(F)F)cc4[nH]3)ccnc2N1.O=C1CCc2c(Oc3ccc4c(c3)[C@@H]3[C@H](O4)[C@H]3c3nc4ccc(C(F)(F)F)cc4[nH]3)ccnc2N1

nearest known ligand 0.89

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

BRAF

The experimentally established mechanism targets of Lifirafenib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 3)

	gene	UniProt	supporting neighbours	confidence
▸	BRAF known ✓	P15056	20/20	0.89

▸	RAF1	P04049	17/20	0.89

▸	ARAF	P10398	1/20	0.89

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
Lifirafenib SCHEMBL29750805	1.00	BRAF (0.89)	BRAFRAF1ARAF
Lifirafenib SCHEMBL29750808	1.00	BRAF (0.89)	BRAFRAF1ARAF
Lifirafenib SCHEMBL29786084	0.95	BRAF (0.80)	BRAFRAF1ARAF
Lifirafenib SCHEMBL20129833	0.94	BRAF (1.00)	BRAFRAF1ARAF
Lifirafenib SCHEMBL29464034	0.94	BRAF (1.00)	BRAFRAF1ARAF
Lifirafenib SCHEMBL24916576	0.94	BRAF (1.00)	BRAFRAF1ARAF
Lifirafenib SCHEMBL29749194	0.94	BRAF (1.00)	BRAFRAF1ARAF
Lifirafenib SCHEMBL15085287	0.94	BRAF (1.00)	BRAFRAF1ARAF
Lifirafenib SCHEMBL15085289	0.94	BRAF (1.00)	BRAFRAF1ARAF
Lifirafenib SCHEMBL15085288	0.94	BRAF (1.00)	BRAFRAF1ARAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
EP-3283486-B1	MALEATE SALTS OF A B-RAF KINASE INHIBITOR, CRYSTALLINE FORMS, METHODS OF PREPARATION, AND USES THEREFORE	BEIGENE LTD (KY)	2022-07-27	—	—	EP	claimed